CM
RYTM icon

Caption Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Caption Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,100
Closed -$5.06M – 2006
2025
Q3 		$5.06M Buy
50,100
+15,100
+43% +$1.4M 0.04% 483
2025
Q2 		$2.21M Sell
35,000
-16,000
-31% -$980K 0.02% 686
2025
Q1 		$2.7M Buy
51,000
+42,300
+486% +$2.35M 0.03% 592
2024
Q4 		$487K Sell
8,700
-182,100
-95% -$10.1M ﹤0.01% 1111
2024
Q3 		$10M Buy
190,800
+140,800
+282% +$6.75M 0.16% 152
2024
Q2 		$2.05M Sell
50,000
-369,300
-88% -$14.7M 0.03% 469
2024
Q1 		$18.2M Sell
419,300
-52,400
-11% -$2.29M 0.28% 83
2023
Q4 		$21.7M Buy
+471,700
New +$14.9M 0.29% 74
2021
Q2 		– Sell
-2,700
Closed -$57K – 1529
2021
Q1 		$57K Hold
2,700
– – ﹤0.01% 977
2020
Q4 		$81K Hold
2,700
– – ﹤0.01% 899
2020
Q3 		$58K Buy
+2,700
New +$61.9K ﹤0.01% 964

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Caption Management's RYTM Position: Q1 2026 in Review

Caption Management sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 4,614 shares — an estimated $494K sold.

Caption Management first reported a position in RYTM in Q2 2024 and held it in 3 quarters. The position peaked at $1.85M in Q2 2024. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Caption Management reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Caption Management sold 4,614 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $494K.
  • Caption Management first reported a position in Rhythm Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Caption Management's Rhythm Pharmaceuticals position peaked at $1.85M in Q2 2024.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.